The indication for the antiepileptic drug lacosamide (LCM) was recently extended to include children from the age of 4 years. Real-life data on the use and serum concentrations of LCM in children and adolescents are limited. The purpose of this study was to investigate the use of LCM in this patient group in relation to age, comedication, dose, serum concentrations and duration of treatment, and to examine pharmacokinetic variability.
INTRODUCTION
Epilepsy is a common neurological disease in children, with antiepileptic drugs (AEDs) being the primary treatment option. Children taking AEDs require particularly close follow-up, as changes in physiology and development affect pharmacokinetic and pharmacodynamic processes. Thus, effect and tolerability can vary significantly between patients and within patients over time. All AEDs have pharmacokinetic variability, and the variability at any age can be considerable, due to factors such as drug interactions, genetic variability, and comorbidities. [1] [2] [3] [4] In recent years, a number of new AEDs have become available, and many are used in children.
Lacosamide (LCM) is indicated as monotherapy and adjunctive therapy for the treatment of focal onset seizures with or without secondary generalization in adults, adolescents, and children from 4 years of age with epilepsy. 5 After initial approval by the European Medicines Agency as add-on in patients 16 years or older in 2008, the indication was extended to include monotherapy in late 2016 and children .4 years in 2017. 6 LCM exerts its effect by selectively enhancing the slow inactivation of voltage-gated sodium channels, in contrast to most other sodium channelblocking AEDs that affect fast inactivation. 7, 8 The National Center for Epilepsy (SSE), Oslo University Hospital, Norway, and the Danish Epilepsy Center, Dianalund, Denmark, provide care for patients suffering from difficult-to-treat epilepsies. A number of these patients are children, some with rare epilepsy syndromes. The laboratories at these 2 hospitals analyze serum concentrations of AEDs in blood samples from inpatients, as well as patients in other hospitals, institutions, and general practice around the country. The reference range for serum concentrations of LCM used in Norway is 10-40 mmol/L (3-10 mg/L), 9 and a recently study has confirmed that efficacy is likely to be obtained within this range in adults. 10 A similar reference range of 9-35 mmol/L is used in Denmark. 11 As clinical trials are performed on carefully selected populations and follow the patients for a limited period, it is important to document real life use of drugs after marketing. 12, 13 Such data regarding the use of LCM in children and adolescents are limited. The purpose of this study was to investigate the use of LCM in children and adolescents in relation to age, comedication, dose, serum concentrations, and duration of treatment and to examine real-life pharmacokinetic variability in this population.
MATERIAL AND METHODS

Study Material
Children and adolescents (,18 years) who had serum concentrations of LCM measured from January 2012 to June 2018 were retrospectively identified from the therapeutic drug monitoring (TDM) databases at the National Center for Epilepsy (SSE), Oslo University Hospital Oslo, Norway, and the Danish Epilepsy Center, Filadelfia, Denmark. Inclusion criteria were at least 1 serum concentration measurement and available information on dose. Measurements below the measuring range were excluded. There is a strong tradition in Scandinavia to use TDM as part of management of patients with epilepsy, and the most common reasons for requesting serum concentration measurements are routine follow-up, dosage adjustments, unsatisfactory seizure control, and adverse effects. In both Norway and Denmark, standard procedure is to perform TDM on samples drawn drug fasting in the morning at assumed steady state, and both laboratories provide information to requesting physicians about this. If it was noted on the request form that the sample was not taken under such conditions, it was excluded from the study. Data on sex, weight, and concomitantly used drugs were collected. Additional clinical data from medical records were available for some of the patients. To avoid introducing bias from multiple samples from individual patients, the most recent measurement with complete data was used when more than 1 result was available.
The study was approved by the local and regional ethics committees.
The number of children/adolescents being prescribed LCM in the period was retrieved from national prescription databases, 14, 15 which contain comparable information. 16 Data on population were retrieved from national agencies for statistics. 17, 18 
Drug Analysis
The analyses were routine measurements by validated methods at the Section for Clinical Pharmacology, The National Center for Epilepsy, Oslo University Hospital, and The Danish Epilepsy Center, Filadelfia, as measured by high performance liquid chromatography-ultraviolet detection (HPLC-UV) and ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Until 2018, an HPLC-UV method was in use in Norway, with a measuring range of 10-250 mmol/L based on Greenway et al. 19 Analyses were performed on an Ultimate 3000 HPLC, Dionex, with a 125 · 3-mm, 3-mm Hypersil BDS C-18 column. In 2018, an UHPLC-MS/MS method was introduced. These analyses were performed on a Prelude MD HPLC/ Endura MD mass spectrometer, using the AEDs ClinMass TDM Platform Kit System (MS9000, MS9200) from Recipe (Munich, Germany). 20 The lower limit of the measuring range was reduced to 3 mmol/L. A complete validation was performed, with no bias toward higher or lower results with the new methodology. At the Danish Epilepsy Center, LCM was analyzed using an in-house LC-MS/MS method applying a Waters Acquity UPLC in connection with a triple quadrupole (TQ) mass detector. Separation was accomplished on a C18 BEH column (Ethylene Bridge Hybrid, C18 1.7 mm 2.1 · 100 mm) and quantified at a measuring range of 2-100 mmol/L, using an in-house calibrator. In both laboratories, the methods are validated and subject to monthly, international proficiency testing.
Calculations
Serum concentrations, doses, concentration/dose (C/D) ratios, and C/(D/kg) ratios were calculated as mean with SD or median with minimum-maximum range to express variability.
The conversion factor for LCM from mmol/L to mg/L is 0.25 (ie, 1 mmol/L = 0.25 mg/L), as the molecular weight of LCM is 250 g/mol. Conversely, the conversion factor from mg/L to mmol/L is 3.99.
When examining the effect of comedication on C/D and C/(D/kg) ratios, patients were grouped according to concomitantly used AEDs: (A) enzyme-inducing AEDs (carbamazepine, phenytoin, and/or phenobarbital), 10, 21 (B) valproate, and (C) reference group, including all patients not included in group A or B.
When comparing data from patients using additional sodium channel-blocking AEDs or not, the following were considered sodium channel blockers: lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine, phenytoin, zonisamide, and rufinamide. 22, 23 When examining the effect of age on pharmacokinetics, the patients were divided into 3 groups: ,6, 6-12, and 13-17 years of age.
Statistical Analyses
For statistical analyses, IBM SPSS Statistics version 25 (IBM, Armonk, NY) was used. For small sample sizes without normal distribution, comparisons were performed by the nonparametric Mann-Whitney rank-sum test or the Kruskal-Wallis test in case of multiple comparisons, with post hoc pairwise Mann-Whitney rank-sum test and Bonferroni correction. For normally distributed data or large samples (.30), Student 2-sided t test with unequal variance was used to calculate significant pairwise differences, and analysis of variance with post hoc Tukey was used for multiple comparisons.
When comparing categorical variables, the Pearson x 2 test was used, alternatively the Fisher exact test (2-sided) when ,80% of the cells in the table had expected frequency . 5 .
P values of ,0.05 were considered statistically significant for all analyses.
RESULTS
Demographic Data
Data from 124 patients, 61 girls and 63 boys, were included in the study, 71 from Norway and 53 from Denmark.
Patient characteristics are summarized in Table 1 . Information on clinical indication for the use of LCM was available in 81 cases; most patients were noted to have focal or multifocal epilepsies. Other indications are listed in Table 1 . LCM was used in monotherapy in 17 patients, while the other patients used 1-3 concomitant AEDs (Table 1) .
Serum Concentrations and Pharmacokinetic Variability
Doses and corresponding serum concentration measurements are shown in Figures 1A, B .
One hundred seventeen patients (94%) had serum concentrations between 9 and 40 mmol/L (2-10 mg/L), that is, within the recommended reference range for one or both countries. The serum concentration was below 25 mmol/L (6 mg/L) (the midvalue of the reference range) in 87 patients.
The C/D ratio varied almost 8-fold between patients (0.03-0.23 mmol/L/mg), whereas the C/(D/kg) ratio varied 7-fold [1.3-9.4 (mmol/L)/(mg/kg), n = 76]. There were no significant differences in age distribution, doses, serum concentrations, or C/(D/kg) ratios between the patients from Norway and Denmark.
There was a statistically significant difference in the ratio between age groups, with the C/(D/kg) ratio being higher in the oldest age group (13-17 years, n = 44) compared both to the middle (6-12 years, n = 29) and the youngest age group (,6 years, n = 3) (Fig. 2) . There was no statistically significant difference in C/(D/kg) ratio between girls (n = 38) and boys (n = 38).
Patients weighing ,50 kg (n = 31) were prescribed higher doses per kg (6.4 mg/kg) than those weighing 50 kg or more (n = 45) (4.8 mg/kg) (P = 0.005). In patients weighing ,50 kg, C/(D/kg) ratio varied 4.5-fold, and in patients weighing 50 kg or more, 4.1-fold.
Concomitant Medication
LCM was used in combination with 20 different AEDs, and the most commonly used concomitant drugs were clobazam (n = 28), levetiracetam (n = 28), valproate (n = 26), lamotrigine (n = 16), and topiramate (n = 14). The number of patients using other AEDs is shown in Figure 3 .
Complete data (including weight) were only available for 3 patients using enzyme-inducing AEDs, and no statistically significant difference in C/(D/kg) compared with the reference group (n = 55) was demonstrated. There was no statistically significant difference in C/(D/kg) ratios between patients using valproate (n = 18) and the reference group (n = 55).
Duration of Treatment
Data on start and discontinuation of therapy were available for 63 patients. In 27 of these patients, treatment was still ongoing at the time of review, and all of these had used LCM for more than 1 year. Eighteen patients had discontinued the drug after less than 1 year, resulting in a 1-year retention rate of 71% (45 of 63 patients). Of the 36 patients who had discontinued the drug at the time of assessment, median duration of use was 365 days (range 30-1247 days).
The 1-year retention rate in patients concomitantly using other sodium channel-blocking AEDs was 56% (14 of 25 patients), in contrast to 82% (31 of 38 patients) in those not using such drugs (P = 0.028).
There was no statistically significant difference in serum concentrations between patients using and not using other sodium channel-blocking AEDs.
Patients who discontinued treatment within the 1st year had lower serum concentrations than those who continued treatment past the 1st year (P = 0.037) (Fig. 1C) . Most of the patients (14 of 18) who discontinued treatment had serum concentration in the lower part [,20 mmol/L (,5 mg/L)] of the reference range. Furthermore, 3 patients had serum concentrations outside both reference ranges [ie, .40 or ,9 mmol/L (.10 or ,2 mg/L)], 1 above and 2 below. None of the 45 patients in the group that continued treatment for more than 1 year had a serum concentration outside this range. 
Prescriptions of LCM in Children and Adolescence in Norway and Denmark
According to nationwide databases covering the whole population in both countries, 47-84 Norwegian and 75-94 Danish outpatients younger than 20 years were prescribed LCM per year between 2012 and 2017 (Danish data only available until 2016). 14, 15 The number of inhabitants ,20 years in the 2 countries is similar, 1,262,730 in Norway and 1,310,918 in Denmark in January 2017. 17, 18 Most of the patients using LCM were 15-19 years old (Fig. 4) , which is also reflected in the age distribution in the current study population.
DISCUSSION
This study describes the use of LCM in a large sample of children and adolescents in 2 Scandinavian countries. Pharmacokinetic variability was demonstrated by variability in C/(D/kg) ratios and was affected by age. The doses and resulting serum concentrations are low or moderate for many of the patients, and the drug is used in combination with numerous other AEDs. More than two-thirds of patients continued treatment beyond 1 year, and retention rates was higher in those not using other sodium channel-blocking AEDs compared with those who did.
Serum Concentrations and Pharmacokinetic Variability
The observed pharmacokinetic variability in children and adolescents was 7-fold between patients, which is less than previously found across all age groups, including adults and elderly. 10, 21 A possible explanation is that a number of diseases causing altered organ function occur only in older age groups. There may also be a degree of selection bias; many of the younger patients had their therapy initiated before regulatory approval, and clinicians may be more conservative with off-label use in patients with significant comorbidities.
The observed lower C/(D/kg) ratio in younger compared with older children and adolescents is in line with previous findings. 21 It is plausible that it reflects an increased clearance of LCM, considering the age-related changes in physiology through childhood. 1, 24 We did not find a significant difference in C/(D/kg) ratio between male patients and female patients, in line with previous findings. 10, 21, 25 In contrast to other studies, no significant effect of enzyme inducing AEDs on the pharmacokinetics of LCM was observed, probably due to the small number of patients in this group. Valproate did not affect the C/(D/kg) ratio of LCM, in line with the other studies. 10, 21, 25, 26 
Duration of Treatment
In postmarketing studies, measurement of retention rates or time to withdrawal is considered to provide relevant clinical information, as it is a measure of effectiveness, a composite of both efficacy and tolerability. 27 We found that 71% of patients continued LCM for more than 1 year, comparable with 65% observed by Ruegger et al. 28 A study of LCM in patients ,21 years of age found that the probability of remaining on LCM without addition of another therapy was 45% at 12 months. 29 Neither of these studies included serum concentration measurements of LCM.
In our study, all patients who continued treatment beyond 1 year had serum concentrations within the combined reference ranges for both countries [9-40 mmol/L (2-10 mg/ L)]. This is in line with results from adults showing that most patients with good clinical effect had serum concentrations within the reference range. 10 We noted that most of the patients who discontinued LCM before 1 year had serum concentrations below or in the lower end of the reference range, and overall, their serum FIGURE 2. Concentration/(dose/kg) ratio in different age groups. The differences between the oldest and the middle and between the oldest and the youngest age groups are statistically significant after Bonferroni correction (*P = 0.003, **P = 0.006).
concentrations were lower than in those who continued treatment past 1 year. This study does not include data on reason for discontinuation, which did not allow for consideration of whether insufficient drug exposure led to discontinuation due to unsatisfactory effect, or whether these patients suffer from adverse effects at low serum concentrations, not permitting the dose to be increased.
Studies on adults have suggested that tolerability of LCM is affected by concomitant use of sodium channelblocking drugs, [30] [31] [32] [33] but results regarding children are conflicting. 28, 29 Most studies on the subject only include "traditional sodium channel blockers"; oxcarbazepine, carbamazepine, phenytoin, and lamotrigine. Based on mechanisms of action, we considered it reasonable to also include rufinamide, eslicarbazepine, and zonisamide. 22, 23 We demonstrated a significant correlation with concomitant use of 1 or more of these 7 drugs and discontinuing LCM treatment within 1 year, suggesting decreased tolerability with such combinations.
Prescriptions of LCM in Children and Adolescence in Norway and Denmark
There has been an increased preference toward using newer AEDs in children and adolescents during the past decade, based on both clinical and population-based evaluations in Norway. 34, 35 The finding that most patients included in our study are in the older age groups is in line with data from the national prescription databases. This is not surprising, considering that until recently the drug was approved only for patients 16 years or older. The presented data from the Norwegian prescription database show that more patients aged 5-14 years were prescribed LCM in 2017 compared with previous years. As the drug received EU approval for pediatric use in September 2017, this number could be expected to increase further in 2018. The number of children and adolescents (,20 years of age) who were prescribed LCM was somewhat higher in Denmark than in Norway, especially early in the studied period, which could be due to differences in treatment tradition or strategy in the 2 countries.
Methodological Considerations
Our study examines a large (n = 124) group of children and adolescents and combines data from serum concentration measurements with clinical information and prescription trends. Some important limitations need to be considered. The established practice for TDM in Norway and Denmark is a standardized sampling time, drug fasting before the morning dose at steady state, but it cannot be assured that this is complied with at all times. Poor adherence cannot be controlled for in a retrospective and naturalistic setting, and clinical data were not available for all patients. Although there is a strong tradition for using TDM in epilepsy treatment in both Norway and Denmark, some patients on LCM therapy may not have had serum concentrations measured. Discontinuation before measurement may result in overestimation of retention rates.
CONCLUSIONS
This study from 2 national epilepsy centers in Scandinavia provides a detailed description of the experience using LCM in children and adolescents by combining TDM, clinical, and prescription data. Pharmacokinetic variability in and between age groups is demonstrated, indicating the usefulness of TDM. More than two-thirds of patients continued treatment beyond 1 year suggesting reasonable effectiveness, and all these patients had serum concentrations within the reference range. One-year retention rates were even higher among patients not concomitantly using other sodium channel-blocking AEDs.
